Yes that matches my understanding. As to where the cells are actually being harvested and expanded, I have no idea.
Agreed that they are using Tigenix's adipose MSC's rather than Mesoblast's bone marrow sourced MSC's for this trial. I did read a paper the other day that compared immunomodulatory responses for MSC's derived from different tissue sources and as I recall both adipose and bone marrow derived cells worked well
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-504
-
- There are more pages in this discussion • 344 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.010(1.09%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 94.0¢ | 89.5¢ | $4.970M | 5.436M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18877 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 6795 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |